REGMF (RemeGen Co) Treasury Stock : $-60.4 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. RemeGen Co's treasury stock for the quarter that ended in Jun. 2024 was $-60.4 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

RemeGen Co Treasury Stock Historical Data

The historical data trend for RemeGen Co's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Treasury Stock Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Get a 7-Day Free Trial

-70.52

-66.42

-61.67

RemeGen Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Treasury Stock	Get a 7-Day Free Trial							-69.64	-66.42	-55.40	-61.67	-60.40

RemeGen Co Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

RemeGen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (OTCPK:REGMF) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

09995:Hong Kong REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

https://www.remegen.com

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.